Chikungunya Vaccine Candidate Induces Strong Immune Response
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, June 13, 2023 -- The live attenuated vaccine candidate for active immunization and prevention of disease caused by chikungunya virus, VLA1553, induces a strong immune response and seroprotective titers in almost all vaccinated persons, according to a study published online June 12 in The Lancet.
Martina Schneider, Ph.D., from Valneva Austria in Vienna, and colleagues conducted a randomized, phase 3 trial involving healthy volunteers aged 18 years and older to examine safety and immunogenicity data up to day 180 after vaccination with VLA1553. Participants were randomly assigned to receive VLA1553 or placebo in a 3:1 ratio (3,093 and 1,035 participants, respectively). The per-protocol population for immunogenicity analysis included 362 participants: 266 and 96 in the VLA1553 and placebo groups, respectively.
The researchers found that VLA1553 induced seroprotective chikungunya virus neutralizing antibody levels in 98.9 percent of the VLA1553 group at 28 days after a single vaccination, independent of age. VLA1553 was generally safe; the adverse event profile was similar to other licensed vaccines and was tolerated equally well in younger and older adults. Overall, 1.5 and 0.8 percent exposed to VLA1553 and placebo, respectively, reported serious adverse events. Only two serious adverse events were considered related to VLA1553 treatment; both participants recovered fully.
"The generation of protective titers in virtually all vaccinated participants independent of age positions VLA1553 as an excellent candidate for the prevention of chikungunya," the authors write.
Several authors disclosed ties to Valneva, which developed VLA1553 and funded the study.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Preparedness for HPAI A(H5N1) Virus Varies Across Jurisdictions
TUESDAY, May 21, 2024 -- Variation is seen in preparedness and response to highly pathogenic avian influenza (HPAI) A(H5N1) viruses, according to a research letter published...
SARS-CoV-2 Vaccine Does Not Increase New-Onset Seizure Risk
TUESDAY, April 30, 2024 -- There is no risk for new-onset seizure incidence for individuals receiving a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine versus...
Most Moms-to-Be Interested in RSV Vaccination During Pregnancy
THURSDAY, April 25, 2024 -- More than half of women who are pregnant or planning to become pregnant are very likely to get vaccinated against respiratory syncytial virus (RSV)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.